Delaney et al. have recently reported that warfarin use has not been linked to an increase in road traffic accidents as previously reported. The finding of no increase in the risk of motor vehicle accidents following warfarin use is reasonable, as there is no evidence that this medicinal drug impairs psychomotor performance. Furthermore, in the summary of product characteristics and package insert within the European Union (EU) it is not mentioned that this drug impairs driving performance, as the authors also indicated for Canada. Within the EU, according to the existing rules, information about the effect of medicinal drugs on driving and the use of machinery should be included in the summary of product characteristics and package insert. Furthermore, a classification regarding the effects of drugs on driving performance has been proposed. Spain introduced a three-level categorization system after Belgium, and warfarin was rated as a non-impairing medicinal drug of driving performance. (Author/publisher)
Abstract